[1]赵 莹.玻璃体腔注射雷珠单抗联合激光治疗糖尿病性黄斑水肿的疗效[J].医学信息,2021,34(07):153-156.[doi:10.3969/j.issn.1006-1959.2021.07.043]
　ZHAO Ying.Curative Effect of Intravitreal Injection of Ranibizumab Combined with Laser in the Treatment of Diabetic Macular Edema[J].Medical Information,2021,34(07):153-156.[doi:10.3969/j.issn.1006-1959.2021.07.043]
点击复制

玻璃体腔注射雷珠单抗联合激光治疗糖尿病性黄斑水肿的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年07期
页码:
153-156
栏目:
药物与临床
出版日期:
2021-04-01

文章信息/Info

Title:
Curative Effect of Intravitreal Injection of Ranibizumab Combined with Laser in the Treatment of Diabetic Macular Edema
文章编号:
1006-1959（2021）07-0153-04
作者:
赵 莹
（盘锦市中心医院眼科，辽宁 盘锦 124000）
Author(s):
ZHAO Ying
(Department of Ophthalmology,Panjin Central Hospital,Panjin 124000,Liaoning,China)
关键词:
雷珠单抗; 黄斑区格栅状光凝治疗; 糖尿病性黄斑水肿
Keywords:
Ranibizumab; Grid photocoagulation treatment in macular area; Diabetic macular edema
分类号:
R774.5
DOI:
10.3969/j.issn.1006-1959.2021.07.043
文献标志码:
A
摘要:
目的 观察雷珠单抗玻璃体腔注射联合激光治疗糖尿病性黄斑水肿的临床疗效。方法 选择2016年12月~2019年12月我院经荧光素眼底血管造影和光学相干断层扫描确诊为糖尿病性黄斑水肿的患者112例（112眼），采用随机数字表法分为激光组和联合组，每组56例（56眼）。激光组患者给予标准黄斑区格栅状光凝治疗，联合组患者在标准黄斑区格栅状光凝治疗前一周给予雷珠单抗玻璃体腔注射。比较两组不同时间点（治疗前、治疗后1周、1、3、6个月）的最佳矫正视力、黄斑中心凹厚度、眼压变化情况及治疗后并发症的发生情况。结果 两组患者最佳矫正视力均得到提高，治疗前及治疗6个月两组的最佳矫正视力比较，差异无统计学意义（P＞0.05）；治疗后1周、1、3个月联合组最佳矫正视力改善程度优于激光组，差异有统计学意义（P＜0.05）；两组治疗前及治疗后6个月黄斑中心凹厚度比较，差异无统计学意义（P＞0.05）；治疗后1周、1、3个月两组黄斑中心凹厚度均下降，且联合组低于激光组，差异有统计学意义（P＜0.05）；两组不同时间点眼压比较，差异无统计学意义（P＞0.05）；激光组并发症发生率为5.36%，联合组并发症发生率为3.57%，两组比较，差异无统计学意义（P＞0.05）。结论 相较于单独激光治疗，玻璃体腔注射雷珠单抗联合激光治疗在提高糖尿病性黄斑水肿患者视力、降低黄斑中心凹厚度等方面短期疗效更佳，两种治疗方法均比较安全。
Abstract:
Objective To observe the clinical efficacy of ranibizumab intravitreal injection combined with laser in the treatment of diabetic macular edema.Methods From December 2016 to December 2019, 112 patients (112 eyes) who were diagnosed with diabetic macular edema by fluorescein fundus angiography and optical coherence tomography in our hospital were selected.Using random number table method, they were divided into laser group and combined group, with 56 cases (56 eyes) in each group.Patients in the laser group were given standard macular grid photocoagulation therapy, and patients in the combination group were given ranibizumab intravitreal injection one week before standard macular grid photocoagulation therapy.The best corrected visual acuity, macular foveal thickness, changes in intraocular pressure and the occurrence of complications after treatment were compared between the two groups at different time points (before treatment, 1 week, 1, 3, and 6 months after treatment).Results The best corrected visual acuity of the two groups was improved. There was no statistically significant difference between the best corrected visual acuity of the two groups before treatment and 6 months after treatment (P＞0.05);The improvement of best corrected visual acuity in the combined group was better than that in the laser group at 1 week, 1, 3 months after treatment,the difference was statistically significant (P＜0.05);Comparison of the thickness of the fovea between the two groups before treatment and 6 months after treatment,the difference was not statistically significant (P＞0.05);The thickness of the fovea in the two groups decreased at 1 week, 1, 3 months after treatment, and the combined group was lower than the laser group, the difference was statistically significant (P＜0.05);There was no statistically significant difference in intraocular pressure between the two groups at different time points (P＞0.05);The complication rate in the laser group was 5.36%, and the complication rate in the combined group was 3.57%. There was no significant difference between the two groups (P＞0.05).Conclusion Compared with laser treatment alone, intravitreal injection of ranibizumab combined with laser treatment has better short-term effects in improving vision and reducing macular foveal thickness in patients with diabetic macular edema. Both treatment methods are relatively safe.

参考文献/References:

[1]李宝,张胜利.糖尿病合并眼底病患者白内障术后黄斑水肿和视力观察[J].西南国防医药,2015,25(12):41-43. [2]薛灿灿,窦宏亮.影响视网膜中央静脉阻塞黄斑水肿视力预后的主要因素[J].中华眼底病杂志,2018(3):291-295. [3]李昆,高丹宇,彭娟.糖尿病患者白内障术后黄斑区视网膜结构的变化[J].国际眼科杂志,2017,17(3):488-491. [4]李素华,高永峰.比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566-568. [5]杨秀芬,韩旭,黄映湘,等.玻璃体腔注射抗VEGF药物对糖尿病性黄斑水肿患者眼部血流动力学的影响[J].临床和实验医学杂志,2019(14):1549-1552. [6]周莉,刘荣,王云松,等.唐山地区糖尿病患者糖尿病性黄斑水肿和视网膜病变患病率及其影响因素分析[J].广西医科大学学报,2018,35(11):1585-1589. [7]潘敏敏.雷珠单抗玻璃体腔内注射联合激光在糖尿病性黄斑水肿中的应用[J].中国实用医刊,2015(1):62-64. [8]金春花,李连喜,李梅芳,等.新诊断2型糖尿病患者视网膜微血管异常的临床特征及危险因素研究[J].中国全科医学,2015,18(5):493-497. [9]张鹏飞,张杰,高荣玉,等.玻璃体内注射血管内皮生长因子(VEGF)抑制剂治疗糖尿病视网膜病变患者的疗效[J].眼科新进展,2018(10):977-981. [10]宋瑜.抗VEGF药物在糖尿病性视网膜病变治疗中的应用[J].医药卫生,2016(7):151-151. [11]阳桥生.黄斑水肿激光光凝不同部位疗效观察[J].临床眼科杂志,2004,12(3):255-256. [12]张菁,蔡小军,陈晓敏,等.玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J].中华眼底病杂志,2015,31(1):22-26. [13]宋爽,喻晓兵,戴虹.玻璃体腔注射雷珠单抗联合曲安奈德或激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J].中华眼底病杂志,2015,31(1):18-21. [14]王海山,张海军,李玉军,等.雷珠单抗玻璃体腔注射并激光光凝治疗糖尿病性黄斑水肿疗效观察[J].中国实用眼科杂志,2015,33(1):25-29. [15]董明霞,王林洪,李冬育,等.PASCAL激光联合玻璃体腔注药治疗糖尿病性黄斑水肿的短期疗效观察[J].眼科,2015,24(5):52-56. [16]陈菲.玻璃体腔注射雷珠单抗治疗糖尿病性黄斑水肿的疗效观察[D].南昌大学,2015. [17]李琰,邵玲,杜敏,等.雷珠单抗联合激光光凝治疗糖尿病性黄斑水肿的疗效[J].国际眼科杂志,2018,18(8):1454-1456. [18]章欣怡,郑小薇,吴锐彬,等.雷珠单抗玻璃体腔注射联合眼底激光治疗糖尿病性黄斑水肿疗效观察[J].现代诊断与治疗,2017,28(4):684-686.

相似文献/References:

[1]王小堂,谢安明.雷珠单抗治疗湿性年龄相关性黄斑变性的视力改善与黄斑形态学变化相关性分析[J].医学信息,2018,31(22):113.[doi:10.3969/j.issn.1006-1959.2018.22.031]
　WANG Xiao-tang,XIE An-ming.Correlation between Visual Acuity Improvement and Morphological Changes of Macular in Treatment of Wet Age-related Macular Degeneration with Ranibizumab[J].Medical Information,2018,31(07):113.[doi:10.3969/j.issn.1006-1959.2018.22.031]
[2]段明明,欧阳君,刘贤升.雷珠单抗与康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的短期疗效比较[J].医学信息,2020,33(04):118.[doi:10.3969/j.issn.1006-1959.2020.04.036]
　DUAN Ming-ming,OUYANG Jun,LIU Xian-sheng.Comparison of Short-term Efficacy of Lucentis and Conbercept in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion[J].Medical Information,2020,33(07):118.[doi:10.3969/j.issn.1006-1959.2020.04.036]
[3]贾晓兰,陆骏麒,彭志佳.眼底激光单用和联合雷珠单抗治疗糖尿病性视网膜病变患者的疗效观察[J].医学信息,2023,36(09):94.[doi:10.3969/j.issn.1006-1959.2023.09.018]
　JIA Xiao-lan,LU Jun-qi,PENG Zhi-jia.Observation on the Curative Effect of Fundus Laser Alone and Combined with Ranibizumab in the Treatment of Patients with Diabetic Retinopathy[J].Medical Information,2023,36(07):94.[doi:10.3969/j.issn.1006-1959.2023.09.018]

更新日期/Last Update: 1900-01-01